Robert Kirkpatrick - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Robert Kirkpatrick

Showing results (31-40 of 33) with videos related to

Pageof 4

Sort By:

You have reached the last page of results.This site can display upto 33 results.

Blood|June 21, 2024

Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemiasMin Chul Kwon, Jan Willem Thuring, Olivier Querolle, et al.

Genome Research|May 5, 2006

Sequencing and analysis of 10,967 full-length cDNA clones from Xenopus laevis and Xenopus tropicalis reveals post-tetraploidization transcriptome remodelingRyan D Morin, Elbert Chang, Anca Petrescu, et al.

Journal of Medicinal Chemistry|April 1, 2026

Optimization of Covalent 6-Cyanoquinazoline KRAS<sup>G12C</sup> Inhibitors for the Treatment of Solid TumorsJesse P Waldo, Paul J Krawczuk, Christopher B Kelly, et al.

Pageof 4

Search research articles

Showing results (31-40 of 33) with videos related to

Sort By:

Pageof 4

You have reached the last page of results.This site can display upto 33 results.

Blood|June 21, 2024

Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemiasMin Chul Kwon, Jan Willem Thuring, Olivier Querolle, et al.

Genome Research|May 5, 2006

Journal of Medicinal Chemistry|April 1, 2026

Optimization of Covalent 6-Cyanoquinazoline KRAS<sup>G12C</sup> Inhibitors for the Treatment of Solid TumorsJesse P Waldo, Paul J Krawczuk, Christopher B Kelly, et al.

Pageof 4